Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

Publication | Closed Access

DOI

Citations

References

2015

Year

José Ignacio Bernardino, Amanda Mocroft, Patrick Mallon, Cédrick Wallet, Jan Gerstoft, Charlotte Russell, Peter Reiss, Christine Katlama, Laura Richert, Abdel Babiker,

The Lancet HIV

Bone BiomarkersHuman RetrovirusAntiretroviral-naive AdultsBone Mineral DensityAntiviral Drug DevelopmentAntiviral TherapyChronic Viral InfectionAntiviral DrugHivMedicineOsteoporosis